Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial
COVID-19(FLARE) 외래 환자의 조기 항바이러스 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 24 hours
48 hour
48 hours
absence
admitted to ICU
aetiology
age
ALT
Analysis
Anosmia
anticipated
antiviral therapy
Antiviral treatment
antivirals
Appendix
Arm
arrhythmia
AST
Asthma
Asymptomatic
Autoimmune
blinded to treatment
Blinding
blood sample
BMI
Breastfeeding
childbearing potential
Cholangitis
chronic
chronic hepatitis
Chronic kidney disease
chronic liver disease
chronic respiratory disease
cirrhosis
clinical condition
collected
combination therapy
Comorbidity
concealed
Concomitant
concomitant medications
conducted
COPD
coryza
cough
COVID-19
COVID-19 disease
COVID-19 vaccine
criteria
current
Date
Day
decrease
defined
Deleterious
detectable
diabetes
died
disease
dissemination
dose
double-blind
Duration
early treatment
effective
EGFR
element
enrolled
enrolment
Ethnicity
examined
exclusion criteria
factorial design
Favipiravir
female
female participant
Fever
followed by
Free
Gender
headache
heart disease
Hepatitis
hepatotoxicity
HIV infection
hospital
hospitalisation
hypersensitivity
hypertension
in viral
include
inclusion criteria
ingredient
investigator
investigators
Ischaemic heart disease
Kidney disease
liver
Liver disease
London
Lopinavir
Lopinavir/ritonavir
malaise
male participant
male participants
measure
medication
Mutation
myalgia
Myocardial infarction
no symptom
non-hospitalised
not limited
number
obesity
objective
observational studies
observational study
oral
outcome
Outpatient
outpatients
participant
Participants
partner
percentage
pharmacokinetic
phase IIa
Placebo
placebo-controlled
placebo-controlled trial
positive
presence or absence
Primary outcome
Proportion of participant
Protease inhibitor
protocol
randomised
randomised controlled trial
Rate
Registered
Registration
respiratory
Respiratory disease
risk
Ritonavir
Safety
Saliva
saliva samples
Sample size
SARS-CoV-2
secondary
Secondary outcomes
Shortness of breath
smoker
smoking
smoking status
Stage
status
steatohepatitis
Stool
Study protocol
supplementary material
Symptom
symptom onset
symptomatic
tested
therapy
Toxicity
Treatment
treatment allocation
Trial
trial medication
Trial registration
undetectable
United Kingdom
upper respiratory tract
vaccine trial
valvular
valvular heart disease
Viral
Viral load
website
with COVID-19
[DOI] 10.1186/s13063-021-05139-2 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05139-2 PMC 바로가기 [Article Type] Letter